Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiographic Image Enhancement | 13 | 2018 | 410 | 2.100 |
Why?
|
| Mammography | 15 | 2018 | 1047 | 1.750 |
Why?
|
| Solitary Pulmonary Nodule | 4 | 2014 | 126 | 1.270 |
Why?
|
| Bone Neoplasms | 7 | 2020 | 2672 | 1.020 |
Why?
|
| Radiography, Thoracic | 5 | 2012 | 474 | 0.970 |
Why?
|
| Radiology | 3 | 2019 | 428 | 0.840 |
Why?
|
| Azygos Vein | 2 | 2011 | 18 | 0.780 |
Why?
|
| Vena Cava, Superior | 2 | 2011 | 78 | 0.750 |
Why?
|
| Task Performance and Analysis | 2 | 2013 | 137 | 0.750 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2020 | 12 | 0.740 |
Why?
|
| ROC Curve | 10 | 2020 | 1246 | 0.740 |
Why?
|
| Chondroblastoma | 1 | 2020 | 16 | 0.730 |
Why?
|
| Osteoblastoma | 1 | 2020 | 15 | 0.730 |
Why?
|
| Osteoma, Osteoid | 1 | 2020 | 24 | 0.730 |
Why?
|
| Chondrosarcoma | 2 | 2020 | 213 | 0.720 |
Why?
|
| Chondroma | 1 | 2020 | 30 | 0.720 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 6 | 2013 | 379 | 0.660 |
Why?
|
| Radiographic Magnification | 2 | 2009 | 15 | 0.640 |
Why?
|
| Calcinosis | 3 | 2011 | 431 | 0.640 |
Why?
|
| Comprehension | 1 | 2019 | 104 | 0.620 |
Why?
|
| Soft Tissue Neoplasms | 4 | 2020 | 918 | 0.620 |
Why?
|
| Mass Screening | 4 | 2011 | 1548 | 0.620 |
Why?
|
| Catheterization, Central Venous | 2 | 2011 | 366 | 0.610 |
Why?
|
| Clinical Competence | 5 | 2014 | 1326 | 0.610 |
Why?
|
| Observer Variation | 11 | 2014 | 721 | 0.600 |
Why?
|
| Osteosarcoma | 2 | 2020 | 948 | 0.450 |
Why?
|
| Breast Diseases | 2 | 2014 | 206 | 0.440 |
Why?
|
| Memory | 2 | 2013 | 445 | 0.420 |
Why?
|
| X-Ray Film | 2 | 2009 | 31 | 0.410 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2012 | 592 | 0.380 |
Why?
|
| Breast Neoplasms | 12 | 2018 | 16252 | 0.370 |
Why?
|
| Muscle Neoplasms | 1 | 2011 | 108 | 0.370 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 123 | 0.370 |
Why?
|
| Catheters | 1 | 2011 | 134 | 0.370 |
Why?
|
| Sensitivity and Specificity | 11 | 2020 | 5194 | 0.360 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 94 | 0.310 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2013 | 7792 | 0.310 |
Why?
|
| Multimodal Imaging | 1 | 2011 | 552 | 0.300 |
Why?
|
| Workload | 1 | 2009 | 200 | 0.290 |
Why?
|
| Precancerous Conditions | 2 | 2011 | 1065 | 0.280 |
Why?
|
| Radiography | 7 | 2019 | 1994 | 0.270 |
Why?
|
| Reproducibility of Results | 9 | 2014 | 6208 | 0.260 |
Why?
|
| Computed Tomography Angiography | 2 | 2018 | 247 | 0.250 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 2197 | 0.210 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 4899 | 0.210 |
Why?
|
| Diagnostic Imaging | 2 | 2020 | 1177 | 0.210 |
Why?
|
| Radiology Information Systems | 3 | 2012 | 118 | 0.200 |
Why?
|
| Artifacts | 3 | 2012 | 536 | 0.200 |
Why?
|
| Lung Neoplasms | 3 | 2013 | 12016 | 0.190 |
Why?
|
| Contrast Media | 3 | 2020 | 1510 | 0.190 |
Why?
|
| Humans | 40 | 2020 | 272039 | 0.190 |
Why?
|
| Clothing | 1 | 2000 | 20 | 0.180 |
Why?
|
| Carcinoma | 1 | 2011 | 2623 | 0.170 |
Why?
|
| Literacy | 1 | 2019 | 7 | 0.170 |
Why?
|
| Acromion | 2 | 1995 | 7 | 0.150 |
Why?
|
| Fibula | 1 | 2018 | 152 | 0.140 |
Why?
|
| Fractures, Spontaneous | 1 | 1997 | 87 | 0.130 |
Why?
|
| Pelvic Bones | 1 | 1997 | 102 | 0.130 |
Why?
|
| Data Display | 2 | 2013 | 52 | 0.130 |
Why?
|
| Female | 24 | 2020 | 149291 | 0.130 |
Why?
|
| Thigh | 1 | 2016 | 164 | 0.130 |
Why?
|
| Gadolinium | 2 | 2020 | 172 | 0.120 |
Why?
|
| Femur | 1 | 1995 | 162 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2020 | 7963 | 0.110 |
Why?
|
| Free Tissue Flaps | 1 | 2018 | 374 | 0.110 |
Why?
|
| Algorithms | 4 | 2012 | 3922 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 1326 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2020 | 920 | 0.100 |
Why?
|
| Forecasting | 2 | 2013 | 705 | 0.100 |
Why?
|
| Breast | 2 | 2016 | 1380 | 0.100 |
Why?
|
| Prevalence | 2 | 2011 | 3417 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 995 | 0.100 |
Why?
|
| Ireland | 1 | 2011 | 31 | 0.100 |
Why?
|
| Bone Remodeling | 1 | 2011 | 102 | 0.090 |
Why?
|
| Preoperative Care | 1 | 2016 | 1553 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2016 | 882 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 1342 | 0.090 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2011 | 168 | 0.090 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 125 | 0.080 |
Why?
|
| Sarcoma | 1 | 2020 | 1841 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 1997 | 1472 | 0.080 |
Why?
|
| Rare Diseases | 1 | 2011 | 360 | 0.080 |
Why?
|
| Efficiency | 1 | 2008 | 94 | 0.070 |
Why?
|
| Professional Competence | 1 | 2009 | 134 | 0.070 |
Why?
|
| User-Computer Interface | 1 | 2009 | 304 | 0.070 |
Why?
|
| Middle Aged | 9 | 2020 | 90457 | 0.070 |
Why?
|
| Calibration | 2 | 2020 | 346 | 0.060 |
Why?
|
| Comorbidity | 1 | 2011 | 2428 | 0.060 |
Why?
|
| Male | 9 | 2020 | 129081 | 0.060 |
Why?
|
| Contrast Sensitivity | 2 | 2013 | 66 | 0.050 |
Why?
|
| United States | 3 | 2011 | 16033 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 10369 | 0.050 |
Why?
|
| Area Under Curve | 2 | 2013 | 728 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2009 | 1324 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 5941 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2012 | 9484 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 2337 | 0.040 |
Why?
|
| Aged | 7 | 2020 | 73500 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 2417 | 0.040 |
Why?
|
| Time Factors | 2 | 2010 | 13135 | 0.040 |
Why?
|
| Organ Motion | 1 | 2018 | 4 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2018 | 66 | 0.040 |
Why?
|
| Probability | 1 | 2020 | 887 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 4512 | 0.040 |
Why?
|
| Texas | 1 | 2009 | 6433 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 126 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2011 | 3153 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2020 | 39828 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2009 | 6882 | 0.030 |
Why?
|
| Rotator Cuff | 1 | 1995 | 23 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 1997 | 336 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1997 | 303 | 0.030 |
Why?
|
| Foot | 1 | 1995 | 110 | 0.030 |
Why?
|
| Risk Factors | 1 | 2011 | 18024 | 0.030 |
Why?
|
| Pattern Recognition, Visual | 1 | 1994 | 40 | 0.030 |
Why?
|
| Radiologists | 1 | 2016 | 178 | 0.030 |
Why?
|
| Adult | 6 | 2012 | 81993 | 0.030 |
Why?
|
| Tibia | 1 | 1995 | 127 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 5105 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 1995 | 160 | 0.030 |
Why?
|
| Liquid Crystals | 1 | 2012 | 3 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2012 | 379 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 1330 | 0.020 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2011 | 75 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 369 | 0.020 |
Why?
|
| Heptanoic Acids | 1 | 2011 | 90 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 754 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 316 | 0.020 |
Why?
|
| Diphosphonates | 1 | 2011 | 264 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2014 | 1043 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 16628 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 917 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1997 | 1240 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1338 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2011 | 273 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 592 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1101 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 534 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 555 | 0.020 |
Why?
|
| Biopsy | 1 | 2014 | 3543 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 1034 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1997 | 1913 | 0.020 |
Why?
|
| Imidazoles | 1 | 2011 | 1061 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 2867 | 0.020 |
Why?
|
| Software | 1 | 2010 | 1386 | 0.010 |
Why?
|
| Decision Making | 1 | 2010 | 1247 | 0.010 |
Why?
|
| Prospective Studies | 2 | 2010 | 13404 | 0.010 |
Why?
|
| Child | 2 | 1995 | 30577 | 0.010 |
Why?
|
| Joint Capsule | 1 | 1995 | 5 | 0.010 |
Why?
|
| Methods | 1 | 1995 | 223 | 0.010 |
Why?
|
| Clavicle | 1 | 1995 | 67 | 0.010 |
Why?
|
| Forearm | 1 | 1995 | 70 | 0.010 |
Why?
|
| Shoulder Joint | 1 | 1995 | 63 | 0.010 |
Why?
|
| Bone Diseases | 1 | 1995 | 142 | 0.010 |
Why?
|
| Cartilage | 1 | 1995 | 112 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1995 | 274 | 0.010 |
Why?
|
| Syndrome | 1 | 1995 | 1407 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 10758 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 31071 | 0.010 |
Why?
|
| Latin America | 1 | 1990 | 126 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1995 | 1850 | 0.010 |
Why?
|
| Japan | 1 | 1990 | 237 | 0.010 |
Why?
|
| Canada | 1 | 1990 | 441 | 0.010 |
Why?
|
| China | 1 | 1990 | 645 | 0.000 |
Why?
|
| Europe | 1 | 1990 | 660 | 0.000 |
Why?
|
| Quality of Health Care | 1 | 1990 | 629 | 0.000 |
Why?
|